

Maike Collienne, Asklepios Klinik Altona, Hamburg

2nd line treatment in metastatic rectal cancer

DISCLOSURE OF INTEREST

- ⦿ There is no conflict of interest.

collapse in the train

- ⊙ m, 69 yrs
- ⊙ pneumonia
 - aggravation of severe polyneuropathy
- ⊙ progressive disease of metastatic rectal cancer

History of rectal cancer

- ⦿ initial diagnosis in 2014:
 - low rectal adenocarcinoma
 - Tx Nx M0, UICC III
 - RAS wild type, BRAF wild-type, MSS
- ⦿ 2014 neoadjuvant chemoradiotherapy and resection
- ⦿ until 2016 perioperative chemotherapy (17 cycles FOLFOX)
 - severe polyneuropathy

History of rectal cancer

- 03/2016 resection of one liver metastasis
- 07/2016 resection of one pulmonary metastasis
- 12/2018 progressive disease:
 - metastases in liver (bilobar), lung (1) and bones (4)

2nd line treatment

- 1st line: FOLFOX – severe polyneuropathy
- 2nd line:
 - FOLFIRI + anti-EGFR-antibody?
 - +/- TACE?

Our recommendation

- ⦿ irinotecan + panitumumab, q2w
- ⦿ re-staging
 - if liver dominant disease: evaluation of (additional) TACE

Thank you for your attention!